Business Context and Reporting Period
This Form 8-K is a current report filed by PerkinElmer, Inc. (Note: The request metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.) on July 26, 2021. The report announces financial results for the second quarter ended July 4, 2021.
Key Financial Metrics
The filing text serves as a notification of results and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the provided text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms that results for the quarter ended July 4, 2021, were announced.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. It explicitly states that the information in this Form 8-K (including Exhibit 99.1) is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the specific financial figures (revenue, EPS, cash flow) by reviewing Exhibit 99.1 (the press release) referenced in this filing.
- Confirm the company name discrepancy: The filing is for PerkinElmer, Inc., not REVVITY, INC. (PerkinElmer later spun off its clinical diagnostics business to form Revvity in 2024).
- Check the trading symbols listed: Common stock (PKI) and 1.875% Notes due 2026 (PKI 21A) on the New York Stock Exchange.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 of the Exchange Act.